Innovus Pharmaceuticals (OTCMKTS:INNVD) versus ProMetic Life Sciences (OTCMKTS:PFSCF) Head-To-Head Survey

Volatility & Risk

ProMetic Life Sciences has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, meaning that its share price is 189% more volatile than the S&P 500.

Earnings and Valuation

This table compares ProMetic Life Sciences and Innovus Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A
Innovus Pharmaceuticals	$23.99 million	0.00	-$8.28 million	($4.16)	N/A

Innovus Pharmaceuticals has lower revenue, but higher earnings than ProMetic Life Sciences.

Insider and Institutional Ownership

0.1% of ProMetic Life Sciences shares are held by institutional investors. Comparatively, 10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares ProMetic Life Sciences and Innovus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%
Innovus Pharmaceuticals	-34.51%	-682.54%	-78.57%

Summary

Innovus Pharmaceuticals beats ProMetic Life Sciences on 6 of the 8 factors compared between the two stocks.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.